Phase 2 N=45 Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus
Epidermoid Carcinoma · Anus
Primary: Percentage of Patients With Complete Response to Treatment — 30; 10; 0; 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=36 A Phase 2 Study of Axalimogene Filolisbac (ADXS11-001) in Participants With Carcinoma of the Anorectal Canal
Anal Cancer · Rectal Cancer
Primary: Percentage of Participants With Best Overall Response According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 — 2.8 percentage of participants
Phase 2 N=63 Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer
Anal Cancer
Primary: Local Failure Rate at 3 Years — 0.259; 0.353 proportion of participants — p=0.218
Phase 2 N=94 A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202)
Squamous Cell Carcinoma of Anal Canal
Primary: Objective Response Rate (ORR) — 13.8 percentage of participants
Phase 3 N=308 Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).
Squamous Cell Carcinoma of the Anal Canal
Primary: Progression-free Survival (PFS) — 9.3; 7.4 months — p=0.0006
Phase 2 N=32 Pembrolizumab in Metastatic Anal Cancer
Anal Cancer
Primary: Overall Response Rate — 11.1 probability
Phase 2 N=45 Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer
Anal Cancer
Primary: Locoregional Failure Rate at 3 Years — 42; 20 percentage of participants
Phase 2 N=8 Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: a Feasibility Trial
Anal Canal Squamous Cell Carcinoma · Stage I Anal Cancer AJCC v8 · Stage II Anal Cancer AJCC v8
Primary: Acute Toxicity — 2 Participants
Phase 3 N=4,446 Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
Anal Cancer · High-grade Squamous Intraepithelial Lesion · HIV Infection
Primary: Anal Cancer Incidence — 173; 402 cases per 100,000 person years
Phase 3 N=91 Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions
Anal Intraepithelial Neoplasia · High-grade Squamous Intraepithelial Lesion · HIV Infection
Primary: Percentage of Participants Achieving Complete Response in 5-FU Arm and Observation Arm Using ITT Population — 5; 9 Participants — p=0.1877
Phase 2 N=63 Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer
Anal Cancer
Primary: Percentage of Subjects With Acute Gastrointestinal (GI) and Genitourinary (GU) Adverse Events (AE) ≥ Grade 2 as Defined by CTCAE v3.0 (Common Terminology Criteria for…
Phase 2 N=20 Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer
Anal Cancer
Primary: 2 Year Failure Free Survival — 20 participants
N/A N=718 The Prevent Anal Cancer Palpation Study
Anal Cancer
Primary: Concordance Between Self-examination and Clinician Examination — 234; 247 Participants
Phase 2 N=8 Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma
Squamous Cell Carcinoma of Skin · Carcinoma, Squamous Cell
Primary: Objective Response Rate (ORR) — 4; 1; 1 Participants
N/A N=276 Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV
Anal Cancer · HIV Infection · Human Papilloma Virus Infection
Primary: Specificity of Each Other Methods of HSIL Detection for APTIMA Assay — 116 Participants
N/A N=240 The Prevent Anal Cancer Self-Swab Study
Anal Cancer
Primary: Compliance With Annual Anal HPV DNA Screening — 107; 89; 13; 31 Participants
N/A N=20 Development of a Health-Related Symptom Index for Participants With and Either Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions
High Grade Anal Canal Squamous Intraepithelial Neoplasia · Human Immunodeficiency Virus
Primary: Development of Spanish-language Version of the Anal Cancer/High-grade Squamous Intraepithelial Lesions (HSIL) Outcomes Research (ANCHOR) Health-related Quality of Life…
Phase 2 N=70 Treatment of Anal High-grade Squamous Intraepithelial Lesions (HSIL) Through Use of a Chinese Herbal Topical Cream
Anus Neoplasms
Primary: Final Response of Anal High-grade Squamous Intraepithelial Lesions (HSIL) — 3; 0; 7; 3 participants — p=.042
Phase 2 N=33 Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus
Anal Cancer · Precancerous Condition
Primary: Proportion of Patients With Regression of Perianal High-grade Squamous Intraepithelial Lesions (HSIL) — 0.515 proportion of participants
Phase 2 N=30 Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis
Penile Cancer
Primary: Number of Participants With Pathologic Complete Remission (pCR) — 3 participants
Phase 2 N=28 Preoperative Chemoradiotherapy and MK-3475 for Esophageal Squamous Cell Carcinoma (ACTS-29)
Esophageal Squamous Cell Carcinoma
Primary: Complete Pathologic Response Rate — 6 Participants
N/A N=10 A Safety and Tolerability of Circumferential Anal Canal Radiofrequency Ablation For Anal Intraepithelial Neoplasia
Anal Intraepithelial Neoplasia (AIN) · High-grade Squamous Intraepithelial Lesions (HSIL)
Primary: Related Adverse Events — 1; 1 number of participants
Phase 3 N=575 Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women
HIV Infections
Primary: Time to the First New Persistent Infection of HPV 6, 11, 16, or 18 — 1.90; 1.04; 2.92; 2.05 Years — p=0.350
Phase 2 N=40 A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract
Head and Neck Squamous Cell Carcinoma
Primary: Change in Immune Response After Tadalafil Administration
N/A N=46 Anal Human Papillomavirus in Inflammatory Bowel Disease Study
Inflammatory Bowel Disease (IBD) · Ulcerative Colitis (UC) · Crohn's Disease (CD)
Primary: Number of Participants With Anal HPV of Any Type, Single Type, and Multiple Types — 41; 16; 25 participants
Phase 2 N=23 VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2
Anal Neoplasm
Primary: Percentage of Participants With no Histologic Evidence of Anal or Anal/Peri-Anal HSIL and no Evidence of HPV-16/18 at Week 36 — 9.1 percentage of participants — p=0.8633
Phase 2 N=12 Preventing Squamous Cell Skin Cancer
Squamous Cell Carcinoma of the Skin
Primary: Mean Number of Squamous Cell Carcinomas — 0.75; 1.00 # of squamous cell carcinomas — p=0.750
Phase 2 N=15 A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma
Cancer
Primary: Toxicities Associated With Combined Radiotherapy and Erlotinib Treatments. — 15; 14; 12; 13 number of adverse events
Phase 2 N=18 Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma (ORPHEUS)
Penile Cancer
Primary: Objective Response Rate (ORR) — 3; 15 Participants
Phase 2 N=50 Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck
Squamous Cell Cancers of the Head and Neck
Primary: Tumor Shrinkage — 2; 9; 36 Participants